Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity

Stephanie K. Dougan, Michael Dougan, Jun Kim, Jacob A. Turner, Souichi Ogata, Hyun Il Cho, Rudolf Jaenisch, Esteban Celis, Hidde L. Ploegh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN) mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ greatly in their affinity for antigen (TRP1(high) or TRP1(low)) as inferred from tetramer dissociation and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1(high) or TRP1(low) mice show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous B16 melanoma. Although naïve TRP1(low) CD8 T cells do not affect tumor growth, upon activation these cells function indistinguishably from TRP1(high) cells in vivo, limiting tumor cell growth and increasing mouse survival. The anti-tumor effect of both TRP1(high) and TRP1(low) CD8 T cells is enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes of T cells conferred by TCR affinity, and they may serve as a platform for screening immunomodulatory cancer therapies.

Original languageEnglish (US)
Pages (from-to)99-111
Number of pages13
JournalCancer Immunology Research
Volume1
Issue number2
DOIs
StatePublished - Aug 1 2013

Fingerprint

T-Lymphocytes
Neoplasms
Melanoma-Specific Antigens
Experimental Melanomas
Immunomodulation
Growth
Early Detection of Cancer
Staining and Labeling
Antigens
Peptides

Keywords

  • B16
  • T cell receptor
  • melanoma
  • somatic cell nuclear transfer
  • tyrosinase related protein 1

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Dougan, S. K., Dougan, M., Kim, J., Turner, J. A., Ogata, S., Cho, H. I., ... Ploegh, H. L. (2013). Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunology Research, 1(2), 99-111. https://doi.org/10.1158/2326-6066.CIR-13-0047

Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. / Dougan, Stephanie K.; Dougan, Michael; Kim, Jun; Turner, Jacob A.; Ogata, Souichi; Cho, Hyun Il; Jaenisch, Rudolf; Celis, Esteban; Ploegh, Hidde L.

In: Cancer Immunology Research, Vol. 1, No. 2, 01.08.2013, p. 99-111.

Research output: Contribution to journalArticle

Dougan, SK, Dougan, M, Kim, J, Turner, JA, Ogata, S, Cho, HI, Jaenisch, R, Celis, E & Ploegh, HL 2013, 'Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity', Cancer Immunology Research, vol. 1, no. 2, pp. 99-111. https://doi.org/10.1158/2326-6066.CIR-13-0047
Dougan, Stephanie K. ; Dougan, Michael ; Kim, Jun ; Turner, Jacob A. ; Ogata, Souichi ; Cho, Hyun Il ; Jaenisch, Rudolf ; Celis, Esteban ; Ploegh, Hidde L. / Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. In: Cancer Immunology Research. 2013 ; Vol. 1, No. 2. pp. 99-111.
@article{e7bcd8d8d5e741ff9dbf3dc8dd19d865,
title = "Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity",
abstract = "We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN) mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ greatly in their affinity for antigen (TRP1(high) or TRP1(low)) as inferred from tetramer dissociation and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1(high) or TRP1(low) mice show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous B16 melanoma. Although na{\"i}ve TRP1(low) CD8 T cells do not affect tumor growth, upon activation these cells function indistinguishably from TRP1(high) cells in vivo, limiting tumor cell growth and increasing mouse survival. The anti-tumor effect of both TRP1(high) and TRP1(low) CD8 T cells is enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes of T cells conferred by TCR affinity, and they may serve as a platform for screening immunomodulatory cancer therapies.",
keywords = "B16, T cell receptor, melanoma, somatic cell nuclear transfer, tyrosinase related protein 1",
author = "Dougan, {Stephanie K.} and Michael Dougan and Jun Kim and Turner, {Jacob A.} and Souichi Ogata and Cho, {Hyun Il} and Rudolf Jaenisch and Esteban Celis and Ploegh, {Hidde L.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0047",
language = "English (US)",
volume = "1",
pages = "99--111",
journal = "Cancer Immunity",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity

AU - Dougan, Stephanie K.

AU - Dougan, Michael

AU - Kim, Jun

AU - Turner, Jacob A.

AU - Ogata, Souichi

AU - Cho, Hyun Il

AU - Jaenisch, Rudolf

AU - Celis, Esteban

AU - Ploegh, Hidde L.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN) mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ greatly in their affinity for antigen (TRP1(high) or TRP1(low)) as inferred from tetramer dissociation and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1(high) or TRP1(low) mice show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous B16 melanoma. Although naïve TRP1(low) CD8 T cells do not affect tumor growth, upon activation these cells function indistinguishably from TRP1(high) cells in vivo, limiting tumor cell growth and increasing mouse survival. The anti-tumor effect of both TRP1(high) and TRP1(low) CD8 T cells is enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes of T cells conferred by TCR affinity, and they may serve as a platform for screening immunomodulatory cancer therapies.

AB - We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN) mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ greatly in their affinity for antigen (TRP1(high) or TRP1(low)) as inferred from tetramer dissociation and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1(high) or TRP1(low) mice show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous B16 melanoma. Although naïve TRP1(low) CD8 T cells do not affect tumor growth, upon activation these cells function indistinguishably from TRP1(high) cells in vivo, limiting tumor cell growth and increasing mouse survival. The anti-tumor effect of both TRP1(high) and TRP1(low) CD8 T cells is enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes of T cells conferred by TCR affinity, and they may serve as a platform for screening immunomodulatory cancer therapies.

KW - B16

KW - T cell receptor

KW - melanoma

KW - somatic cell nuclear transfer

KW - tyrosinase related protein 1

UR - http://www.scopus.com/inward/record.url?scp=84888065568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888065568&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0047

DO - 10.1158/2326-6066.CIR-13-0047

M3 - Article

VL - 1

SP - 99

EP - 111

JO - Cancer Immunity

JF - Cancer Immunity

SN - 2326-6066

IS - 2

ER -